December 25, 2013
The dipeptidyl peptidase-4 (DPP-4) inhibitor Tenelia 20 mg tablets (teneligliptin) now carries an indication of “type 2 diabetes” without any restrictions on its concurrent use, Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo said on December 20. Concomitant-use restrictions for the...read more